KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy

BACKGROUND: Two previous first-line studies showed an improved trend in response rate (RR) and progression free survival (PFS) in metastatic colorectal cancer (CRC) patients with KRAS mutation. Others have reported a worsened outlook for metastatic CRC patients with KRAS mutation and a higher likeli...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Sharma, Neelesh, Saifo, Maher, Tamaskar, Ila R, Bhuvaneswari, Ramkumar, Mashtare, Terry, Fakih, Marwan
Формат: Artigo
Язык:Inglês
Опубликовано: Pioneer Bioscience Publishing Company 2010
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3397582/
https://ncbi.nlm.nih.gov/pubmed/22811812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2010.022
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы